Bladder cancer is common and one of the most costly cancer forms, due to a lack of curative therapies. Recently, clinical safety and efficacy of the alpha1-oleate complex was demonstrated in a placebo-controlled study of nonmuscle invasive bladder cancer. Our study investigated if long-term therapeutic efficacy is improved by repeated treatment cycles and by combining alpha1-oleate with low-dose chemotherapy. Rapidly growing bladder tumors were treated by intravesical instillation of alpha1-oleate, Epirubicin or Mitomycin C alone or in combination. One treatment cycle arrested tumor growth, with a protective effect lasting at least 4 weeks in mice receiving 8.5 mM of alpha1-oleate alone or 1.7 mM of alpha-oleate combined with Epirubicin or Mitomycin C. Repeated treatment cycles extended protection, defined by a lack of bladder pathology and a virtual absence of bladder cancer-specific gene expression. Synergy with Epirubicin was detected at the lower alpha1-oleate concentration and in vitro, alpha1-oleate was shown to enhance the uptake and nuclear translocation of Epirubicin, by tumor cells. Effects at the chromatin level affecting cell proliferation were further suggested by reduced BrdU incorporation. In addition, alpha1-oleate triggered DNA fragmentation, defined by the TUNEL assay. The results suggest that bladder cancer development may be prevented long-term in the murine model, by alpha1-oleate alone or in combination with low-dose Epirubicin. In addition, the combination of alpha1-oleate and Epirubicin reduced the size of established tumors. Exploring these potent preventive and therapeutic effects will be of immediate interest in patients with bladder cancer.

Department of Microbiology Immunology and Glycobiology Institute of Laboratory Medicine Lund University Lund Sweden

Department of Urology Motol Hospital and 2nd Faculty of Medicine Charles University Prague Czech Republic

See more in PubMed

Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447-461.

Svanborg C, Agerstam H, Aronson A, et al. HAMLET kills tumor cells by an apoptosis-like mechanism: cellular, molecular, and therapeutic aspects. Adv Cancer Res. 2003;88:1-29.

Fischer W, Gustafsson L, Mossberg AK, et al. Human alpha-lactalbumin made lethal to tumor cells (HAMLET) kills human glioblastoma cells in brain xenografts by an apoptosis-like mechanism and prolongs survival. Cancer Res. 2004;64:2105-2112.

Storm P, Klausen TK, Trulsson M, et al. A unifying mechanism for cancer cell death through ion channel activation by HAMLET. PLoS One. 2013;8:e58578.

Mossberg AK, Hou Y, Svensson M, Holmqvist B, Svanborg C. HAMLET treatment delays bladder cancer development. J Urol. 2010;183:1590-1597.

Hien TT, Ambite I, Butler D, et al. Bladder cancer therapy without toxicity-a dose-escalation study of alpha1-oleate. Int J Cancer. 2020;147:2479-2492.

Brisuda A, Ho J, Kandiyal PS, et al. Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex. Nat Commun. 2021;12:1-16.

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. Update March 2008. Arnhem, The Netherlands: European Association of Urology, 2008. Eur Urol. 2008;54:303-314.

Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27:295-300.

Van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56:430-442.

Sharma P, Zargar-Shoshtari K, Sexton WJ. Valrubicin in refractory non-muscle invasive bladder cancer. Expert Rev Anticancer Ther. 2015;15:1379-1387.

Hu Q, Sun W, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev. 2016;98:19-34.

Arends TJ, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate-and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2016;69:1046-1052.

Plosker GL, Faulds D. Epirubicin. Drugs. 1993;45:788-856.

Böhle A, Jurczok A, Ardelt P, et al. Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo. J Urol. 2002;167:357-363.

Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008;53:709-719.

Malmström P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56:247-256.

Chou R, Selph S, Buckley DI, et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol. 2017;197:1189-1199.

Barlogie B, Drewinko B. Lethal and cytokinetic effects of mitomycin C on cultured human colon cancer cells. Cancer Res. 1980;40:1973-1980.

Kang Y, Greaves B, Perry RR. Effect of acute and chronic intermittent hypoxia on DNA topoisomerase IIα expression and mitomycin C-induced DNA damage and cytotoxicity in human colon cancer cells. Biochem Pharmacol. 1996;52:669-676.

Barthel BL, Mooz EL, Wiener LE, Koch GG, Koch TH. Correlation of in situ oxazolidine formation with highly synergistic cytotoxicity and DNA cross-linking in cancer cells from combinations of doxorubicin and formaldehyde. J Med Chem. 2016;59:2205-2221.

Olinski R, Jaruga P, Foksinski M, Bialkowski K, Tujakowski J. Epirubicin-induced oxidative DNA damage and evidence for its repair in lymphocytes of cancer patients who are undergoing chemotherapy. Mol Pharmacol. 1997;52:882-885.

Nadeem A, Ho JC, Tran TH, et al. Beta-sheet-specific interactions with heat shock proteins define a mechanism of delayed tumor cell death in response to HAMLET. J Mol Biol. 2019;431:2612-2627.

Ho J, Rydstrom A, Manimekalai MSS, Svanborg C, Grüber G. Low resolution solution structure of HAMLET and the importance of its alpha-domains in tumoricidal activity. PLoS One. 2012;7:e53051.

Vásquez JL, Ibsen P, Lindberg H, Gehl J. In vitro and in vivo experiments on electrochemotherapy for bladder cancer. J Urol. 2015;193:1009-1015.

Yanagie H, Fujino T, Yanagawa M, et al. Tumor growth suppression with novel intra-arterial chemotherapy using eepirubicin-entrapped water-in-oil-in-water emulsion in vivo. In Vivo. 2021;35:239-248.

Hien TT, Garcia-Vaz E, Stenkula KG, et al. MicroRNA-dependent regulation of KLF4 by glucose in vascular smooth muscle. J Cell Physiol. 2018;233:7195-7205.

Gomhor J, Alqaraghuli H, Kashanian S, Rafipour R, Mahdavian E, Mansouri K. Development and characterization of folic acid-functionalized apoferritin as a delivery vehicle for epirubicin against MCF-7 breast cancer cells. Artif Cell Nanomed Biotechnol. 2018;46:S847-S854.

Xu L, Tu Z, Xu G, et al. Epirubicin directly promotes hepatitis B virus (HBV) replication in stable HBV-expressing cell lines: a novel mechanism of HBV reactivation following anticancer chemotherapy. Mol Med Rep. 2014;9:1345-1350.

Nadeem A, Sanborn J, Gettel DL, et al. Protein receptor-independent plasma membrane remodeling by HAMLET: a tumoricidal protein-lipid complex. Sci Rep. 2015;5:16432.

Hansen JS, Tran TH, Cavalera M, et al. Peptide-oleate complexes create novel membrane-bound compartments. Mol Biol Evol. 2020;37:3083-3093.

Cersosimo RJ, Hong WK. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986;4:425-439.

Lamm SH, Byrd DM, Kruse MB, Feinleib M, Lai S-H. Bladder cancer and arsenic exposure: differences in the two populations enrolled in a study in Southwest Taiwan. Biomed Environ Sci. 2003;16:355-368.

Chiong E, Esuvaranathan K. New therapies for non-muscle-invasive bladder cancer. World J Urol. 2010;28:71-78.

Moussa M, Papatsoris AG, Dellis A, Abou Chakra M, Saad W. Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2020;20:965-983.

Kamat AM, Lerner SP, O'Donnell M, et al. Evidence-based assessment of current and emerging bladder-sparing therapies for non-muscle-invasive bladder cancer after bacillus Calmette-Guerin therapy: a systematic review and meta-analysis. Eur Urol Oncol. 2020;3:318-340.

Slovacek H, Zhuo J, Taylor JM. Approaches to non-muscle-invasive bladder cancer. Curr Oncol Rep. 2021;23:1-11.

Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22:107-117.

Shore ND, Redorta JP, Robert G, et al. Non-muscle-invasive bladder cancer: an overview of potential new treatment options. Urol Oncol. 2021;39:642-663.

de Jong JJ, Hendricksen K, Rosier M, Mostafid H, Boormans JL. Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients. Bladder Cancer. 2018;4:395-401.

Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21:4270-4276.

Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22:919-930.

Clinical and molecular response to alpha1-oleate treatment in patients with bladder cancer

BAMLET administration via drinking water inhibits intestinal tumor development and promotes long-term health